A New Phase III Trial of ODM-201 for Men with Castrate Resistant Prostate Cancer without Visible Metastases

Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company) have announced that they have begun enrollment in a randomized Phase III clinical trial of a new investigational treatment for men with advanced prostate cancer. ODM-201 is a novel, oral androgen receptor inhibitor. The trial named ARAMIS trial is a randomized, Phase III, multi-center, double-blind, placebo-controlled trial and has been designed to evaluate the efficacy and safety of ODM-201 in men with castration-resistant prostate cancer (CRPC) who have rising PSA levels and no detectable metastases. The trial is designed to determine the effects of ODM-201 on men’s metastasis-free survival. The trial [...]